Generation Bio Co reports results for the quarter ended December 31 - Earnings Summary

Generation Bio

14/03/2025 12:00

Generation Bio Co GBIO.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -53 cents.  The mean expectation of seven analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -38 cents to -18 cents per share.

Revenue rose 45.5% to $4.19 million from a year ago; analysts expected $2.50 million.

Generation Bio Co's reported EPS for the quarter was a loss of 32 cents​.

The company reported a quarterly loss of $21.38 million.

Generation Bio Co shares had fallen by 51.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Generation Bio Co is $6.50

This summary was machine generated from LSEG data March 14 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.30
-0.32
Missed
Sep. 30 2024
-0.28
-0.23
Beat
Jun. 30 2024
-0.28
-0.31
Missed
Mar. 31 2024
-0.41
-1.12
Missed